CPIX CPIX
Company Profile ↓Company Overview
CPIX (CPIX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $44.52M (+17.6% YoY); net profit $-2.84M.
- Trailing 12 Months Year-on-year growth — revenue +17.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.14% |
| 1 Year: | 17.57% |
Stock Price Performance
| 1 Year: | +88.28% |
| 6 Months: | +156.89% |
| 3 Months: | +113.98% |
| 1 Month: | +54.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)70.15 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 11.20M | - | 8.59M | 10.16M | 8.49M | - | 8.73M | 9.42M | 6.94M | - | 8.33M | 9.60M | 9.25M | - | 10.54M | 9.06M | 8.07M | - | 11.18M | 10.30M | 11.41M | 9.12M | 9.22M | 10.89M | 10.09M | 9.35M | 8.50M | 9.85M | 9.09M | 10.44M | 11.71M | 10.84M | 8.29M | 13.68M | 9.13M |
| Operating Income | -105.31K | 130.13K | -957.37K | -657.80K | -1.68M | -839.35K | -903.33K | -2.45M | -868.98K | -1.81M | -2.26M | -1.32M | -1.37M | -3.20M | -3.39M | -1.85M | -1.58M | -1.21M | -1.75M | -324.30K | -1.44M | -1.56M | -4.35M | -1.29M | -1.85M | -288.59K | -2.28M | -1.53M | 22.86K | -1.87M | -6.18M | -1.87M | -1.03M | -1.69M | -1.84M | 1.29M | -747.48K | -1.97M | -1.37M | -3.13M |
| Net Income | -48.04K | 106.17K | -749.69K | -1.27M | -5.16M | -743.03K | -800.54K | -2.38M | -720.69K | -1.64M | -2.22M | -73.88K | -549.51K | -1.95M | -960.71K | -1.06M | -918.27K | -481.74K | -883.78K | 166.83K | 1.23M | -1.06M | -3.85M | -1.39M | -1.34M | -408.64K | -2.44M | 192.18K | 872.20K | -1.05M | -6.29M | -1.95M | -1.09M | -1.54M | -1.90M | 1.26M | -740.74K | -1.94M | -1.41M | -3.29M |
| Diluted EPS | 0.00 | 0.01 | -0.05 | -0.08 | -0.32 | -0.05 | -0.05 | -0.15 | -0.05 | -0.11 | -0.14 | 0.00 | -0.04 | -0.13 | -0.06 | -0.07 | -0.06 | -0.03 | -0.06 | 0.01 | 0.08 | -0.07 | -0.26 | -0.09 | -0.09 | -0.03 | -0.17 | 0.01 | 0.06 | -0.07 | -0.44 | -0.14 | -0.08 | -0.11 | -0.14 | 0.08 | -0.05 | -0.13 | -0.09 | -0.22 |
| R&D Expense | 678.78K | 644.66K | - | 898.36K | 1.08M | 943.16K | - | 1.87M | 1.45M | 1.31M | - | 1.40M | 1.72M | 1.67M | - | 1.72M | 1.42M | 1.23M | - | 1.26M | 1.36M | 1.45M | - | 1.75M | 1.82M | 1.71M | - | 1.50M | 1.15M | 1.92M | - | 1.16M | 1.06M | 1.31M | - | 1.30M | 1.47M | 1.25M | - | 1.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.54M | 45.88M | 51.14M | 700.00K | 800.00K | 600.00K | 900.00K | 32.48M | 40.38M | 28.80M | 32.41M | 35.84M | 35.05M | 42.01M | 39.55M | 37.87M | 44.52M |
| Operating Income | 5.78M | 6.50M | 9.85M | 8.82M | -3.80M | 3.56M | 1.11M | -1.43M | -4.08M | -11.17M | -9.29M | -6.38M | -7.68M | -5.70M | -9.55M | -6.43M | -2.79M |
| Net Income | 3.09M | 2.46M | 5.66M | 5.84M | -2.10M | 2.42M | 731.35K | -944.68K | -7.98M | -6.96M | -3.54M | -3.34M | -3.51M | -5.57M | -6.28M | -6.48M | -2.84M |
| Diluted EPS | 0.17 | 0.12 | 0.28 | 0.30 | -0.11 | 0.14 | 0.04 | -0.06 | -0.50 | -0.45 | -0.23 | -0.22 | -0.24 | -0.38 | -0.44 | -0.46 | -0.19 |
| R&D Expense | 4.99M | 4.33M | 5.03M | 5.10M | 5.62M | 3.39M | 3.85M | 3.19M | 4.28M | 7.58M | 6.87M | 5.77M | 5.68M | 6.69M | 5.83M | 4.82M | 5.57M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 92.05M | 95.52M | 98.59M | 87.61M | 95.41M | 91.92M | 93.40M | 93.23M | 112.69M | 104.55M | 96.46M | 84.46M | 92.93M | 81.78M | 75.58M | 76.82M |
| Total Equity | - | 72.22M | 77.78M | 82.93M | 85.70M | 79.47M | 80.76M | 76.89M | 73.25M | 64.12M | 55.84M | 51.12M | 46.99M | 42.81M | 36.27M | 29.60M | 22.85M | 24.88M |
| Cash & Equivalents | 11.83M | 78.70M | 65.89M | 70.60M | 54.35M | 40.87M | 39.87M | 38.20M | 34.51M | 45.41M | 27.94M | 28.21M | 24.75M | 27.04M | 19.76M | 18.32M | 17.96M | 11.44M |
| Total Liabilities | - | - | 14.34M | 12.68M | 13.03M | 8.32M | 14.65M | 15.10M | 20.28M | 29.31M | 57.12M | 53.46M | 49.59M | 41.86M | 56.95M | 52.52M | 53.04M | 52.28M |
| Current Liabilities | - | - | 9.23M | 6.60M | 8.06M | 7.55M | 13.75M | 12.41M | 14.79M | 17.69M | 27.80M | 24.15M | 25.67M | 19.28M | 28.58M | 27.98M | 31.62M | 36.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 404.97K | 346.66K | 8.72M | 7.14M | 746.13K | 6.69M | 5.88M | 569.48K | -557.71K | 3.11M | 3.06M | 5.42M | 6.34M | 8.45M | 6.09M | -612.19K | 4.93M |
| Investing Cash Flow | -712.34K | -768.64K | -437.77K | -19.18M | -5.07M | -6.03M | -2.34M | -3.12M | 9.51M | -27.72M | 2.30M | -1.76M | -501.89K | -13.67M | -105.69K | 57.84K | -4.71M |
| Financing Cash Flow | 67.18M | -12.39M | -3.58M | -4.21M | -9.15M | -1.66M | -5.19M | -1.15M | 1.95M | 7.14M | -5.08M | -7.12M | -3.55M | -2.06M | -7.42M | 196.90K | -6.75M |
| Capital Expenditure | -601.80K | -577.16K | -257.50K | -464.89K | -97.41K | -163.26K | -142.97K | -130.87K | -275.96K | -455.57K | -246.20K | -140.82K | -103.53K | -102.15K | -281.27K | -66.46K | -97.90K |
| Free Cash Flow | -196.83K | -230.50K | 8.46M | 6.67M | 648.71K | 6.53M | 5.73M | 438.61K | -833.67K | 2.66M | 2.81M | 5.27M | 6.24M | 8.35M | 5.81M | -678.65K | 4.83M |
| Share Buybacks | 27.30M | 4.85M | 4.25M | 8.09M | 4.80M | 4.32M | 5.34M | 2.52M | 3.72M | 2.88M | 3.49M | 1.85M | 1.39M | 1.05M | 740.53K | 579.05K | 263.48K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 13.3% | 14.2% | 19.3% | 1,259.7% | -475.2% | 593.1% | 123.5% | -4.4% | -10.1% | -38.8% | -28.7% | -17.8% | -21.9% | -13.6% | -24.2% | -17.0% | -6.3% |
| Net Margin % | 7.1% | 5.4% | 11.1% | 834.6% | -263.1% | 404.0% | 81.3% | -2.9% | -19.8% | -24.2% | -10.9% | -9.3% | -10.0% | -13.3% | -15.9% | -17.1% | -6.4% |
| ROE % | 4.3% | 3.2% | 6.8% | 6.8% | -2.6% | 3.0% | 1.0% | -1.3% | -12.4% | -12.5% | -6.9% | -7.1% | -8.2% | -15.4% | -21.2% | -28.4% | -11.4% |
| ROCE % | - | 7.8% | 11.1% | 9.7% | -4.7% | 4.4% | 1.4% | -1.8% | -5.4% | -13.2% | -11.6% | -9.0% | -11.8% | -8.9% | -17.8% | -14.6% | -7.0% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CPIX
Cumberland Pays $1.50 Dividend After Apotex Brand Sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOU2tsVVZ4cjEteVlWQldJRFlLT1dobUJpaFl1ekNtY21SZVpkUU1NV3Jzc2s1eFhlSjg0YVBmaFNRNWc5LVVtUFVHNHRSdzJCMmlGRkRZTEwxYzduak9GZjRiRVpBV3kxVS1wZnRqR0FLdU4yOEszV0ZDUzlUcVVUQW1aLVRWWVpfelQtOU…
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQd3hDNnVuRlk2d3I5eWZxeTBfNElpNzZORFRoeUFKUFhta1V0dUYweWE4Ykp5Sk05ZzNUc1BnUFY0UUpuV1R1c29waXJIeFRkQ2JTTHhkcnlQdktPdEFOdzlDWXBwWW9wNTN0anV0OG5zcXpNVC1sSzNKeFdJVm1ZbzFodzY3cFRkcnI2b2…
CPIX|Cumberland Pharmaceuticals Inc|Price:6.680|Chg%:-0.050 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE41RVlqSzN1WlVRcE1YYUVlWlZaZ0VsbnlYU0YtQ1dEMnpxT1FXSWZFUWFObk41Z2d4WTEtY3JVa2Y5LV9lcmxLalpWMjc4RWZvLWdmMkFhaW1OZ2s0aFlrakFhaHBEZ3NCZFdnZHlR?oc=5" target="_blank">CPIX|Cumberland Pha…
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPdGRXemFoM2h0cnVrMWN4UnBCZXRlOTV0TG5vV192NkZrbG1LUEFQQmwzV0RkelB2V05aUG1vcXdfUGVXWXZ1ek5aaGMxYmh2bmdqT25xRmxmb29XY2lTSGR2ZlRlSEp2cVhORDdFU2ZOc0FrSGRUZWdiT25SdDNib0NMemFWQkEyNS1CbD…
Cumberland Pharmaceuticals (CPIX) jumps on $100 million Apotex asset-sale deal | CPIX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOVjk1dzdpY195YldvLVNoSFZ2TVJHU01JNlgxQXZYcmNpZHlvZlU0RWhuYjktMmptQ2t5WWhRN2RlZ1hvdXFtclhmTE54RnlSeGhQTzFlTVItc1BmbVA1ZUlFX0cwNVlDT05taWM1bHpjZjhIY011VUwySGJkUmpfXzlIVG9WV01nMjlnej…
Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPQlZYWHNKbjFxc3lqZ3p4VXdqQjVtOXhCOVNyallFOExrWUlxRmhRTjZJanBMTWtDemVLNFNlSU1GeXVteUNMemE3YVhVeFZBaDMyTGszTDhfV0p5YVhGd1lWVmZlalgydkJwVkJIdkJpLXNzVjZKSEFlTTk1cXFWQ0VkbkxHT0kzMk14d3…
CPIX — Frequently Asked Questions
What is the current share price of CPIX?
As of 2026-08-05 17:25 PDT, CPIX trades at $7.55 on NASDAQ/NYSE. Its 52-week range is $1.47 to $7.77.
What is the P/E ratio of CPIX?
CPIX trades at a trailing price-to-earnings (P/E) ratio of -39.74.
What is the return on equity (ROE) of CPIX?
CPIX has a return on equity (ROE) of -11.40%. Its return on capital employed (ROCE) is -6.97%.
Is CPIX a good stock to buy?
This page provides a data-driven analysis of CPIX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.